mRNA Vaccines Produce T-cell Immunity Against COVID-19

Researchers from the USA have shown that mRNA vaccines, Pfizer/BioNTech, and Moderna are effective at generating T-cell immunity against SARS-CoV-2. The study published on a pre-print server revealed that vaccinated individuals had diminished T-cell responses against the SARS-CoV-2 variants that emerged in the U.K. (B.1.1.7), South Africa (B.1.351), and Brazil (P1).

The team used two standardized assays to measure T-cell immunity to the wild-type and variant SARS-CoV-2 spike proteins in peripheral blood samples taken from 29 vaccinated, previously uninfected individuals and 25 convalescent individuals who had recovered from mild COVID-19. In the vaccinated individuals (11 Pfizer/BioNTech, 18 Moderna), the T-cell response was measured before inoculation, and then at a median of 22 days (range 16–30 days) following a first dose and at a median of 59 days following the first dose (range 38–204 days) when all vaccinees had also received a second dose.

The team reports that T-cell responses to the wild-type spike protein increased significantly from baseline after an initial vaccine dose, even as soon as 7 days following immunization. Following a second dose, the median spike-specific T cell responses were higher in the vaccinees than in the convalescent individuals. The T-cell response to pools of the spike variants B.1.1.7, B.1.351, and P.1 among vaccinated individuals was decreased to 84.6% of the response to wild-type spike for the B.1.1.7 lineage, to 70.2% for the B.1.315 lineage, and 83.4% for the P.1 lineage.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1

#Featured